4th Annual ICI Boston

ICI Boston is focused exclusively on how to deliver maximum clinical benefit through immune checkpoint modulation as the backbone of immuno-oncology.

The ongoing torrent of successes and setbacks from the leaders in the field have shown there is still much to be learned about what it takes to develop clinically successful checkpoint drugs and combination strategies.

Rather than broad, general overviews of the IO space, this meeting will deliver specific, granular insights on the preclinical, translational and clinical challenges that drug developers face in advancing checkpoint modulators onto the market successfully.